Disc Medicine (IRON) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.58
- EPS estimate
- −$1.13
- EPS surprise
- −40.05%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 7, 2025
Disc Medicine's most recent results in the table are for Q2 2025, reported on August 7, 2025. The company posted a loss of $1.58 per share, wider than the −$1.13 estimate by 40.05%. No revenue was reported and no revenue estimate was given. Compared with Q2 2024, the loss per share widened by about 53%, from $1.03.
Disc Medicine has reported a loss in all 16 quarters in the table. Annual losses were $18.10 per share in 2021, then far smaller at $3.42 in 2023 and $3.96 in 2024. Fiscal 2022 is incomplete here, with no rows for its first two quarters, and its Q4 shows an unusually large loss of $11.23 per share. Since 2023, quarterly losses have ranged from $0.58 to $1.58 per share, with Q2 2025 the widest in that span. Over the last eight quarters, the company beat the EPS estimate five times and missed three times.
The table has not been updated since the Q2 2025 report. In earlier years, Disc Medicine reported Q3 results in early to mid-November, between November 9 and November 15. Later quarters will show whether losses stay near 2023 and 2024 levels and whether any revenue appears.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$1.13 | −$1.58 | −40.05% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | −$1.11 | −$1.02 | +7.87% | $0.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$1.10 | −$0.95 | +13.31% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.04 | −$0.89 | +14.17% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.10 | −$1.03 | +6.74% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$1.01 | −$1.09 | −8.11% | $0.00 | SEC |
| Q4 2023 | Mar 21, 2024 | −$0.77 | −$0.90 | −16.69% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.80 | −$0.58 | +27.50% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$0.86 | −$0.74 | +14.28% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.67 | −$1.20 | −79.88% | $0.00 | SEC |
| Q4 2022 | Mar 31, 2023 | −$0.81 | −$11.23 | −1295.03% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$5.90 | −$3.32 | +43.73% | $0.00 | — |
| Q4 2021 | Mar 10, 2022 | −$4.98 | −$4.10 | +17.59% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$4.53 | −$4.30 | +5.15% | $0.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$3.67 | −$3.80 | −3.64% | $0.00 | SEC |
| Q1 2021 | May 13, 2021 | −$3.53 | −$5.90 | −66.98% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Disc Medicine (IRON) last report earnings?
Disc Medicine last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did IRON beat earnings estimates?
No. Disc Medicine reported EPS of −$1.58 for Q2 2025 against a −$1.13 estimate — a 40.05% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.